Biogen’s Alzheimer’s Drug Leqembi Sales Soar, But Can They Keep Up?
Boston, MA – Biogen, a pharmaceutical company based in Cambridge, Massachusetts, exceeded market expectations for first-quarter profit as a result of cost-cutting measures. Despite facing fierce competition for its older drugs, the company’s shares rose nearly 7% prior to the market opening. One of Biogen’s key highlights was the performance of its Alzheimer’s drug Leqembi, in partnership with Eisai, which saw a significant increase in sales to approximately $19 million. Although this figure fell short …